New combo shows promise for hard-to-treat ovarian cancer
NCT ID NCT02867956
First seen Mar 21, 2026 · Last updated Jun 15, 2026 · Updated 13 times
Summary
This study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that had stopped responding to platinum-based chemotherapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants took the drugs by mouth and were monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.